ArticleBreast cancer research and treatment2026
Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUse of adjuvant endocrine therapy (ET) for ductal carcinoma in situ (DCIS) varies widely in clinical practice. We investigated oestrogen receptor (ER) testing, the initiation of ET, and the effect of ET on outcomes for DCIS in New Zealand.
methodsWomen with DCIS (2000-2022) were identified from the New Zealand Breast Cancer Foundation National Register and linked to the national pharmaceutical data. Logistic regression identified factors associated with ER testing, and cumulative incidence of breast cancer events was estimated with death as a competing risk.
resultsAmong 5813 women with DCIS, 894 patients (15.4%) had ER testing, with the rate increasing from 11.1% in 2000 to 23.3% in 2006, before declining to 13.9% in 2022. The Waikato region contributed 65.6% of ER tests. In Waikato, testing was more likely among women who received adjuvant radiotherapy after breast-conserving surgery, likely reflecting a site-specific clinical practice. In other regions, testing was more frequent among older women, Māori ethnicity, those with symptomatic presentation, and those with DCIS size > 20 mm, potentially reflecting selective testing. Among 729 patients with ER-positive DCIS, only 183 (25.1%) commenced ET, of whom 80.3% were in Waikato. ET users had the lowest cumulative risk of breast cancer event, but differences were not statistically significant.
conclusionsER testing and initiation of ET for DCIS remained low, except in Waikato, where clinical centres participated in ET trials and ER testing became more common. Standardised ER testing and greater clinician participation in clinical trials may lead to improved evidence-based care. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.